Gracell Biotechnologies Presents Updated Clinical Data from FasTCAR-T GC012F Demonstrating Deep and Durable Responses in Newly Diagnosed Multiple Myeloma at ASH 2023
11 déc. 2023 19h30 HE
|
Gracell Biotechnologies Inc.
Minimal residual disease negativity (MRD-) observed in all treated patients in the ongoing study, with 95% (21/22) achieving stringent complete response (sCR) through a median follow-up of 18.8 months...
亘喜生物在ASH 2023年会上以口头报告发表FasTCAR-T GC012F治疗多发性骨髓瘤新确诊患者的最新临床数据，治疗应答深入且持久
11 déc. 2023 19h30 HE
|
Gracell Biotechnologies Inc.
该临床研究正在开展中，所有接受治疗的患者均达到微小残留病灶阴性（MRD-），且 95%（21/22）的患者达到严格完全缓解（sCR），中位随访时间为18.8个月 GC012F是一款基于FasTCAR平台开发的B细胞成熟抗原（BCMA）和CD19双靶点自体CAR-T疗法，目前正在多项临床研究中评估其治疗多类血液肿瘤和自身免疫性疾病的效果 ...
Gracell Biotechnologies Announces FDA Clearance of IND Application for Phase 1/2 Clinical Trial of FasTCAR-T GC012F for the Treatment of Refractory Systemic Lupus Erythematosus
27 nov. 2023 08h00 HE
|
Gracell Biotechnologies Inc.
Gracell is pioneering use of a CD19/BCMA dual-targeted CAR-T cell therapy in refractory systemic lupus erythematosus, aiming for deeper and wider depletion of disease-causing antibody secreting cells...
亘喜生物宣布FasTCAR-T GC012F治疗难治性系统性红斑狼疮的1/2期新药临床试验（IND）申请获美国FDA正式批准
27 nov. 2023 08h00 HE
|
Gracell Biotechnologies Inc.
亘喜生物开创性地将CD19/BCMA双靶点CAR-T细胞疗法用于治疗难治性系统性红斑狼疮，旨在更深入、广泛地清除致病性抗体分泌细胞（ASCs）及B细胞 FasTCAR-T GC012F在既往一系列的由研究者发起的临床试验（IIT）中，针对60例多发性骨髓瘤和B细胞非霍奇金淋巴瘤患者，展示了深入应答的疗效以及卓越的安全性优势 中国江苏苏州、上海和美国加利福尼亚州圣迭戈, Nov. 27,...
Gracell Biotechnologies to Participate in Inaugural Cell Therapy for Autoimmune Disease Summit
16 nov. 2023 08h00 HE
|
Gracell Biotechnologies Inc.
Presentation to focus on application of next-generation CAR-T cell therapy technologies for treatment of autoimmune disease Gracell to highlight translational research supporting CD19/BCMA...
Gracell Biotechnologies Reports Third Quarter 2023 Unaudited Financial Results and Provides Corporate Update
13 nov. 2023 07h30 HE
|
Gracell Biotechnologies Inc.
Dosed first patient in Phase 1b/2 clinical trial in the US evaluating FasTCAR-T GC012F for the treatment of relapsed/refractory multiple myeloma (RRMM) Expect to commence Phase 1/2 clinical trial in...
亘喜生物荣膺“BioTech Breakthrough奖项” 之“年度免疫学解决方案综合奖”
08 nov. 2023 08h30 HE
|
Gracell Biotechnologies Inc.
第三届国际性“BioTech Breakthrough奖项”旨在表彰为生命科学和生物技术领域带来深远影响的解决方案、服务及企业 获奖在研产品GC012F是一款基于FasTCAR平台开发的自体CAR-T细胞疗法，目前正在多项临床研究中评估其针对多种血液肿瘤和自身免疫性疾病的效果 中国江苏苏州、上海和美国加利福尼亚州圣迭戈, Nov. 08, 2023 (GLOBE NEWSWIRE) --...
Gracell Biotechnologies Wins Overall Immunology Solution of the Year by BioTech Breakthrough Awards Program
08 nov. 2023 08h30 HE
|
Gracell Biotechnologies Inc.
Third annual BioTech Breakthrough Award recognizes excellence in life science and biotechnology solutions, services and companies GC012F, a FasTCAR-enabled autologous CAR-T cell therapy, is...
Gracell Biotechnologies to Present Updated Results from BCMA/CD19 Dual-Targeting FasTCAR-T GC012F in Newly Diagnosed Multiple Myeloma at the 65ᵗʰ American Society of Hematology Annual Meeting & Exposition
02 nov. 2023 09h00 HE
|
Gracell Biotechnologies Inc.
Oral presentation of the updated results from ongoing Phase 1 investigator-initiated study of GC012F in frontline setting for transplant-eligible, high-risk newly diagnosed multiple myeloma ...
Gracell Biotechnologies to Participate in Four Upcoming Investor Conferences
01 nov. 2023 16h00 HE
|
Gracell Biotechnologies Inc.
Gracell Biotechnologies to participate in four investor conferences